Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors
✍ Scribed by Charlotte Chaulet; Cécile Croix; David Alagille; Sylvain Normand; Adriana Delwail; Laure Favot; Jean-Claude Lecron; Marie-Claude Viaud-Massuard
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 620 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
✦ Synopsis
Several thalidomide analogues were synthesized and compared to thalidomide and its more active analogue, lenalidomide, for their ability to inhibit the production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α and interleukin (IL)-6 by LPS-activated peripheral blood mononuclear cells (PBMCs). Among these compounds, two analogues containing sulfonyl group displayed interesting downregulation of TNF-α and IL-6 production.
📜 SIMILAR VOLUMES
A three substituted urea derivative, SA13353 (compound 1a), exhibited potent inhibitory activity against lipopolysaccharide (LPS)-induced TNF-alpha production. We focused on the 1,1-substituted moiety (R(1) and R(2)) of SA13353 and investigated substituent effects of this moiety on LPS-induced TNF-a
## Abstract For Abstract see ChemInform Abstract in Full Text.
## Abstract A series of 2‐aminoisonicotinic acid derivatives such as (I) and (II) is synthesized and evaluated for their in vitro HIF‐1 inhibitory activity.